Home » Authors » Trista Morrison

Articles by Trista Morrison

Sofinnova Closes $375M Fund To Support Spinouts

Nov. 15, 2006

By Trista Morrison

Vasogen Brings In $20.3M To Fund Celacade, VP025 Programs

Nov. 10, 2006

By Trista Morrison

Bradley Licenses U.S. Rights To BioSante's Bio-E-Gel Product

Nov. 9, 2006

By Trista Morrison

Bradley Licenses U.S. Rights To BioSante's Bio-E-Gel Product

Nov. 9, 2006

By Trista Morrison

Celgene Raises $1B As Part Of Addition To S&P 500 Index

Nov. 7, 2006

By Trista Morrison

Celgene Raises $1B As Part Of Addition To S&P 500 Index

Nov. 7, 2006

By Trista Morrison

Exelixis' Stock Falls After XL999 Phase II Suspension

Nov. 3, 2006

By Trista Morrison

Exelixis' Stock Falls After XL999 Phase II Suspension

Nov. 3, 2006

By Trista Morrison

Critical Therapeutics Gets $20M, Bets On Zileuton CR

Nov. 2, 2006

By Trista Morrison

Critical Therapeutics Gets $20M, Bets On Zileuton CR

Nov. 2, 2006

By Trista Morrison

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...